Marker Therapeutics enters $750K manufacturing deal with director-owned CDMO Cell Ready

Marker Therapeutics, Inc.

3-year Master Services Agreement with Cell Ready LLC, owned by director/shareholder John Wilson.
Work Order #1 for GMP drug product for MT-401 and/or MT-601; projected sum ≤$750K for Q1 2024.
Agreement includes customary reps, warranties, and indemnification; either party may terminate for breach or insolvency.
Additional work orders expected for the remainder of 2024.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Marker Therapeutics, Inc. entered into Master Services Agreement for Product Supply with Cell Ready LLC valued at $750,000 (effective 2024-02-22).

Action: entry
Agreement: supply
Counterparty: Cell Ready LLC
Value: $750,000
Effective: 2024-02-22

Exact text from the filing

(the “Company”) entered into a Master Services Agreement for Product Supply (the “Agreement”) with Cell Ready LLC (“Cell Ready”).

View on SEC.gov

757 material agreements filed in the last 30 days. Browse all material agreements →

Marker Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-027293

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.